Ambrosia Biosciences Inc.
PrivateLast Round
Series B
Mar 31, 2026
Est. Valuation
$203M
Total Funding Raised
$141M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Ambrosia Biosciences Inc. operates in Healthcare & Life Sciences and is based in Boulder, Colorado. Its latest recorded funding round was a Series B round in March 2026.
Ambrosia Biosciences Inc. is a biotechnology company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ambrosia Biosciences Inc. Comparables
Compare Ambrosia Biosciences Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Eccogene | 89% | |
| Regor Therapeutics Group | 89% | |
| Verdiva Bio | 86% |
For institutional investors. Book with your work email.
Ambrosia Biosciences Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 31, 2026 | ||||
| Series A | Dec 10, 2024 | ||||
| Series A | Aug 20, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ambrosia Biosciences Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Redmile Group | Series B |
| Janus Henderson Group | Series B |
| Blue Owl Capital | Series B |
| Deep Track Capital | Series B |
| BVF Partners L.P. | Series A, Series B |
| Boulder Ventures | Series B, Series A |
| Samsara BioCapital | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 67% MoM.
- Apr 21, 2026
Presenting at the American Diabetes Association's 86th Scientific Session.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 10, 2026
Ambrosia Biosciences Inc. plans to present two late-breaking posters featuring the nonclinical profiles of its novel oral small molecule GLP-1 receptor agonist and GIP receptor antagonist at ObesityWeek(R) 2026, the Obesity Society's 44th Annual Meeting, in Washington, D.C., on Nov 14-17 '26.
For institutional investors. Book with your work email.
Ambrosia Biosciences Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ambrosia Biosciences Inc.'s valuation, stock price, and market status.
Is Ambrosia Biosciences Inc. a public or private company?
Ambrosia Biosciences Inc. is a private company.
What is the current stock price of Ambrosia Biosciences Inc.?
Ambrosia Biosciences Inc. is a private company, so its shares have no public market price. Caplight tracks Ambrosia Biosciences Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ambrosia Biosciences Inc. worth (valuation)?
Ambrosia Biosciences Inc.'s valuation is estimated at $203.0M based on funding round data.
Can I buy Ambrosia Biosciences Inc. stock?
Ambrosia Biosciences Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ambrosia Biosciences Inc.'s last funding round?
Ambrosia Biosciences Inc.'s most recent funding round was Series B on March 31, 2026.
Who are the main investors in Ambrosia Biosciences Inc.?
Key investors in Ambrosia Biosciences Inc. include Redmile Group, Blue Owl Capital, Deep Track Capital, BVF Partners L.P., Boulder Ventures.
Will Ambrosia Biosciences Inc. IPO soon?
No public IPO plans have been announced for Ambrosia Biosciences Inc..
How can I track Ambrosia Biosciences Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Ambrosia Biosciences Inc.'s shares on secondary markets.